Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial

Efficacy and safety of ARNI in highrisk patients in the PIONEERHF trial
5' education - Dec. 19, 2019 - Prof. David Morrow, MD
  • Overview

    A subanalysis of the PIONEER-HF trial was performed to examine whether sacubitril/valsartan was effective and safe in high-risk subgroups. Prof Morrow gives a brief presentation of this analysis.

  • Educational information

    This video was recorded at the AHA in Philadelphia, USA, on November 17, 2019.

  • Faculty

    Dr. David A. Morrow is the director of the Cardiac Intensive Care Unit (CICU) at Brigham and Women’s Hospital (BWH). A cardiovascular medicine specialist, he is also a professor of medicine at Harvard Medical School (HMS), Boston, MA, USA.

  • Disclosures

    This educational series is funded by an unrestricted educational grant provided by Novartis. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free